Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

367 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Progenitor-like cell type of an MLL-EDC4 fusion in acute myeloid leukemia.
Schuster LC, Syed AP, Tirier SM, Steiger S, Seufert I, Becker H, Duque-Afonso J, Ma T, Ogawa S, Mallm JP, Lübbert M, Rippe K. Schuster LC, et al. Among authors: lubbert m. Blood Adv. 2023 Nov 28;7(22):7079-7083. doi: 10.1182/bloodadvances.2022009096. Blood Adv. 2023. PMID: 37820244 Free PMC article. No abstract available.
Development of combination therapies with BTK inhibitors and dasatinib to treat CNS-infiltrating E2A-PBX1+/preBCR+ ALL.
Gentile G, Poggio T, Catalano A, Voutilainen M, Lahnalampi M, Andrade-Martinez M, Ma T, Sankowski R, Goncharenko L, Tholen S, Han K, Morgens DW, Prinz M, Lübbert M, Engel S, Hartmann TN, Cario G, Schrappe M, Lenk L, Stanulla M, Duyster J, Bronsert P, Bassik MC, Cleary ML, Schilling O, Heinäniemi M, Duque-Afonso J. Gentile G, et al. Among authors: lubbert m. Blood Adv. 2024 Jun 11;8(11):2846-2860. doi: 10.1182/bloodadvances.2023011582. Blood Adv. 2024. PMID: 38598725 Free PMC article.
Similar efficacy outcomes with peripheral blood stem cell versus bone marrow for autologous stem cell transplantation in acute myeloid leukemia: Long-term follow-up of the EORTC-GIMEMA randomized AML-10 trial.
Baron F, Efficace F, Cannella L, Stevens-Kroef M, Amadori S, de Witte T, Lübbert M, Venditti A, Suciu S. Baron F, et al. Among authors: lubbert m. Am J Hematol. 2024 Mar;99(3):486-489. doi: 10.1002/ajh.27196. Epub 2024 Jan 4. Am J Hematol. 2024. PMID: 38174977
15-year remission in refractory FLT3-mutated AML attained by sorafenib.
Rummelt C, Pfeifer D, Wäsch R, Zeiser R, Duyster J, Finke J, Lübbert M. Rummelt C, et al. Among authors: lubbert m. Ann Hematol. 2024 Nov;103(11):4801-4803. doi: 10.1007/s00277-024-06012-3. Epub 2024 Sep 25. Ann Hematol. 2024. PMID: 39317884 Free PMC article. No abstract available.
Activity of decitabine combined with all-trans retinoic acid in oligoblastic acute myeloid leukemia: results from a randomized 2x2 phase II trial (DECIDER).
Rummelt C, Grishina O, Schmoor C, Crysandt M, Heuser M, Götze KS, Schlenk RF, Döhner K, Salih HR, Heil G, Müller-Tidow C, Brugger W, Kündgen A, De Wit M, Giagounidis A, Scholl S, Neubauer A, Krauter J, Bug G, Al-Ali HK, Wäsch R, Becker H, May AM, Duyster J, Hackanson B, Ganser A, Döhner H, Lübbert M. Rummelt C, et al. Among authors: lubbert m. Haematologica. 2023 Aug 1;108(8):2244-2248. doi: 10.3324/haematol.2022.282258. Haematologica. 2023. PMID: 36601981 Free PMC article. Clinical Trial. No abstract available.
367 results